0001493152-18-011777.txt : 20180814 0001493152-18-011777.hdr.sgml : 20180814 20180814160814 ACCESSION NUMBER: 0001493152-18-011777 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180814 DATE AS OF CHANGE: 20180814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vitality Biopharma, Inc. CENTRAL INDEX KEY: 0001438943 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 753268988 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53832 FILM NUMBER: 181017484 BUSINESS ADDRESS: STREET 1: 1901 AVENUE OF THE STARS, 2ND FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90067 BUSINESS PHONE: 530-231-7800 MAIL ADDRESS: STREET 1: 1901 AVENUE OF THE STARS, 2ND FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90067 FORMER COMPANY: FORMER CONFORMED NAME: Stevia First Corp. DATE OF NAME CHANGE: 20111020 FORMER COMPANY: FORMER CONFORMED NAME: Legend Mining Inc. DATE OF NAME CHANGE: 20080630 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

[ ]

TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 000-53832

VITALITY BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Nevada

75-3268988

(State or other jurisdiction of

incorporation or organization )

(I.R.S. Employer

Identification No.)

1901 Avenue of the Stars, 2^nd Floor
Los Angeles, CA		90067
(Address of principal executive offices)		(Zip Code)

(530) 231-7800

Registrant’s telephone number, including area code

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes[X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]

Accelerated filer [ ]

Non-accelerated filer [ ]

(Do not check if a smaller reporting company)

Smaller reporting company [X]

Emerging growth company [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

As of August 13, 2018, there were 24,350,147 shares of the registrant’s common stock outstanding.

VITALITY BIOPHARMA, INC.

Quarterly Report on Form 10-Q

For the Quarterly Period Ended

June 30, 2018

INDEX

PART I - FINANCIAL INFORMATION	3

Item 1. Financial Statements (unaudited)	3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3. Quantitative and Qualitative Disclosures About Market Risk	21
Item 4. Controls and Procedures	21

PART II - OTHER INFORMATION	23

Item 1. Legal Proceedings	23
Item 1A. Risk Factors	23
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 6. Exhibits	24

SIGNATURES	25

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)

VITALITY BIOPHARMA, INC.

CONDENSED FINANCIAL STATEMENTS

THREE MONTHS ENDED JUNE 30, 2018 AND 2017

(Unaudited)

CONDENSED UNAUDITED BALANCE SHEETS	4

CONDENSED UNAUDITED STATEMENTS OF OPERATIONS	5

CONDENSED UNAUDITED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIENCY)	6

CONDENSED UNAUDITED STATEMENTS OF CASH FLOWS	7

NOTES TO THE CONDENSED UNAUDITED FINANCIAL STATEMENTS	8

VITALITY BIOPHARMA, INC.

CONDENSED BALANCE SHEETS

	June 30, 2018			March 31, 2018
		(unaudited)
Assets

Current Assets
Cash	$	173,037		$	656,290
Accounts receivable, net		6,611			13,843
Prepaid expense, related party		-			2,600
Prepaid expenses		3,058			3,058

Total Assets	$	182,706		$	675,791

Liabilities and Stockholders’ Equity (Deficiency)

Current Liabilities
Accounts payable and accrued liabilities	$	347,790		$	200,475
Derivative liability		170,435			153,042

Total liabilities		518,225			353,517

Commitments and contingencies

Stockholders’ Equity (Deficiency)
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 24,312,647 and 24,275,147 shares issued and outstanding, respectively		24,112			24,075
Additional paid-in-capital		22,820,524			22,343,135
Accumulated deficit		(23,180,155	)		(22,044,936	)
Total stockholders’ equity (deficiency)		(335,519	)		322,274
Total liabilities and stockholders’ equity (deficiency)	$	182,706		$	675,791

The accompanying notes are an integral part of these condensed financial statements.

VITALITY BIOPHARMA, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended June 30,
	2018			2017

Revenue	$	26,328		$	27,043
Cost of goods sold		25,748			20,486
Gross profit		580			6,557

Operating expenses:
General and administrative		523,184			673,789
Research and development		587,422			407,009
Rent - related party		7,800			7,500
Total operating expenses		1,118,406			1,088,298

Loss from operations		(1,117,826	)		(1,081,741	)

Other income (expenses)
Change in fair value of derivative liability		(17,393	)		(24,612	)
Total other expenses, net		(17,393	)		(24,612	)
Net loss	$	(1,135,219	)	$	(1,106,353	)

Net loss per common share
Basic and diluted	$	(0.05	)	$	(0.05	)
Weighted average number of common shares outstanding
Basic and diluted		24,290,806			22,255,290

The accompanying notes are an integral part of these condensed financial statements.

VITALITY BIOPHARMA, INC.

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIENCY)

THREE MONTHS ENDED JUNE 30, 2018 AND 2017

(Unaudited)

					Additional
	Common Stock				Paid-in-		Accumulated
Description	Shares		Amount		Capital		Deficit			Total

Balance- March 31, 2018		24,275,147	$	24,075	$	22,343,135	$	(22,044,936	)	$	322,274
Fair value of vested restricted common stock						106,881		—			106,881
Fair value of vested stock options		—		—		321,420		—			321,420
Fair value of common stock issued for services		37,500		37		49,088		—			49,125
Net loss		—		—		—		(1,135,219	)		(1,135,219	)

Balance- June 30, 2018 (unaudited)		24,312,647	$	24,112	$	22,820,524	$	(23,180,155	)	$	(335,519	)

The accompanying notes are an integral part of these condensed financial statements.

VITALITY BIOPHARMA, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended June 30,
	2018			2017

Operating activities
Net loss	$	(1,135,219	)	$	(1,106,353	)
Adjustments to reconcile net loss to net cash used in operating activities
Fair value of vested stock options		321,420			342,540
Fair value of vested restricted common stock		106,881			102,584
Fair value of common stock issued for services		49,125			100,000
Change in fair value of derivative liability		17,393			24,612
Fair value of vested warrants granted to employees		—			—
Changes in operating assets and liabilities:
Accounts receivable		7,232			(6,134	)
Prepaid expense, related party		2,600			—
Accounts payable and accrued liabilities		147,315			(66,913	)
Accounts payable - related party		-			(12,500	)
Net cash used in operating activities		(483,253	)		(622,164	)

Net decrease in cash		(483,253	)		(622,164	)

Cash and cash equivalents - beginning of period		656,290			1,152,766
Cash and cash equivalent - end of period	$	173,037		$	530,602

Supplemental disclosure of cash flow information:
Cash paid during the period for:
Interest	$	—		$	—
Income taxes	$	—		$	—

The accompanying notes are an integral part of these condensed financial statements.

VITALITY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

THREE MONTHS ENDED JUNE 30, 2018 AND 2017

(Unaudited)

1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. The Company’s fiscal year end is March 31.

In 2015, the Company developed a new class of cannabinoids known as cannabosides, which were discovered through application of the Company’s proprietary enzymatic bioprocessing technologies originally developed for stevia sweeteners. In 2016, the Company received approvals from the U.S. Drug Enforcement Administration (the “DEA”) and the State of California to initiate studies and manufacturing scale-up at its research and development facilities in order to develop cannabosides.

In May 2016, we received shareholder and board approval for a name change to Vitality Biopharma, Inc., an exchange of one (1) share of the Company’s common stock for each 10 shares of common stock outstanding or exercisable under any outstanding warrants or option agreements, and an increase in the number of shares of authorized common stock from 525,000,000 to 1,000,000,000. These corporate changes became effective on July 20, 2016.

Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended June 30, 2018, the Company incurred a net loss of $1,135,219 and used cash in operating activities of $483,253. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s March 31, 2018 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that as of June 30, 2018 we have sufficient funds to operate the business for the next six months. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, licensing or acquiring new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.

We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

Basis of Presentation of Unaudited Condensed Financial Information

The unaudited condensed financial statements of the Company for the three months ended June 30, 2018 and 2017 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2018 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2018 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 28, 2018. These financial statements should be read in conjunction with that report.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.

Financial Assets and Liabilities Measured at Fair Value

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:

Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3		Unobservable inputs based on the Company’s assumptions.

The fair value of the derivative liabilities of $170,435 and $153,042 at June 30, 2018 and March 31, 2018, respectively, were valued using Level 2 inputs.

The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2018, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.

Stock-Based Compensation

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

The Company periodically issues unvested (“restricted”) shares of its common stock to employees as equity incentives. The Company’s restricted stock vests upon the satisfaction of a recipient’s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company’s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period.

Basic and Diluted Loss Per Share

Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:

	Three months ended
	June 30, 2018		June 30, 2017
Options		3,316,710		2,820,489
Warrants		1,135,003		372,421
Total		4,451,713		3,192,910

Research and Development

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred.

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company will adopt ASU 2016-02 on April 1, 2019, and does not believe the adoption of ASU 2016-02 will have a material impact on its financial statements and related disclosures.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features. ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company plans to adopt ASU 2017-11 on April 1, 2019. The adoption of ASU 2017-11 is not expected to have an impact on the Company’s financial statements and related disclosures because the conversion feature of the Company’s warrants have features other than down round provisions that require the current accounting treatment and classification.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” The ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently assessing the effect that the ASU will have on our financial position, results of operations, and disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

2. DERIVATIVE LIABILITY

In May 2015, the Company issued certain warrants which included an anti-dilution provision that allows for the automatic reset of the exercise price of the warrants upon future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants. In addition, the Company determined that the warrants can be settled for cash at the holders’ option in a future fundamental transaction, as defined. As a result of the anti-dilution and fundamental transaction provisions, the Company determined that the conversion feature of the warrants should be separated from the host contract, be recognized as a derivative liability, and re-measured at each reporting period with the change in value reported in the statement of operations.

At March 31, 2018, the balance of the derivative liabilities was $153,042. During the three months ended June 30, 2018, the Company recorded an increase in derivative liability of $17,393. At June 30, 2018, the balance of the derivative liabilities was $170,435.

At June 30, 2018 and March 31, 2018, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions:

	June 30, 2018			March 31, 2018
Conversion feature:
Risk-free interest rate		2.52	%		1.73-2.27	%
Expected volatility		119	%		121	%
Expected life (in years)		2 years			.25 to 2.15 years
Expected dividend yield		—			—

Fair Value:
Conversion feature	$	170,435		$	153,042

The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.

3. STOCKHOLDERS’ EQUITY (DEFICIENCY)

Common stock issued to employees with vesting terms

The Company has issued shares of common stock to employees and directors that vest over time. The fair value of these stock awards are based on the market price of the Company’s common stock on the dates granted, and are amortized over vesting terms ranging up to three years.

During the three months ended June 30, 2018, we recorded expense related to the fair value of stock awards that vested of $106,881. At June 30, 2018, the amount of unvested compensation related to these awards is approximately $240,000, and will be recorded as expense over 1 year.

Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board. In the event a recipient’s employment or service with the Company terminates, any or all of the shares of common stock held by such recipient that have not vested as of the date of termination under the terms of the restricted stock agreement are forfeited to the Company in accordance with such restricted grant agreement.

The following table summarizes restricted common stock activity:

	Number of Shares
Non-vested shares, April 1, 2018		918,085
Granted		—
Vested		—
Forfeited		—
Non-vested shares, June 30, 2018		918,085

Common stock issued for services

During the three months ended June 30, 2018, the Company issued a total of 37,500 shares of common stock to one consultant as payment for services and recorded expenses of $49,125 based on the fair value of the Company’s common stock at the issuance date.

4. STOCK OPTIONS

A summary of the Company’s stock option activity during the three months ended June 30, 2018 is as follows:

	Shares			Weighted Average Exercise Price
Balance outstanding at March 31, 2018		3,316,710		$	1.40
Granted		50,000			1.62
Exercised		—
Expired		(60,000	)		2.00
Cancelled		—
Balance outstanding at June 30, 2018		3,306,710		$	1.40
Balance exercisable at June 30, 2018		2,255,648		$	1.22

A summary of the Company’s stock options outstanding and exercisable as of June 30, 2017 is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- date Stock Price
Options Outstanding, June 30, 2018		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		527,500	$	1.50-1.81	$	1.50
		687,500	$	2.00 – 2.79	$	2.00 – 2.79
		123,334	$	3.10 – 3.80	$	3.10 – 3.80
		45,834	$	4.00 – 4.70	$	4.00 – 4.70
		3,306,710
Options Exercisable, June 30, 2018		1,259,980	$	0.50	$	0.50
		101,500	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		147,500	$	1.50-1.81	$	1.50-1.81
		447,500	$	2.00 – 2.79	$	2.00 – 2.79
		123,334	$	3.10 – 3.80	$	3.10 – 3.80
		45,834	$	4.00 – 4.70	$	4.00 – 4.70
		2,255,648

During the three months ended June 30, 2018, we expensed total stock-based compensation related to stock options of $321,420, and the remaining unamortized cost of the outstanding stock-based awards at June 30, 2018 was approximately $934,000. The remaining unamortized cost will be amortized on a straight line basis over a weighted average remaining vesting period of one year. At June 30, 2018, the 3,306,710 outstanding stock options had an intrinsic value of approximately $2,400,000.

5. WARRANTS

At June 30, 2018, warrants to purchase common shares were outstanding as follows:

	Shares			Weighted Average Exercise Price
Balance at March 31, 2018		1,164,422		$	2.19
Granted		—			—
Exercised		—			—
Expired		(29,419	)	$	4.25
Balance outstanding and exercisable at June 30, 2018		1,135,003		$	2.19

At June 30, 2018, the 1,135,003 outstanding warrants had no intrinsic value.

6. RELATED PARTY OBLIGATIONS

On April 23, 2012, the Company entered into a lease agreement with One World Ranches, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Company’s Board of Directors, and his wife, to rent the space being used as the Company’s principal office and laboratory facility. The original term of the lease was from May 1, 2012 to May 1, 2017. In May 2017, the Company extended the lease through May 1, 2020. Our rent payments thereunder were $2,300 per month until May 1, 2017 and increased to $2,600 per month on May 1, 2017. Aggregate payments under the lease for the three months ended June 30, 2018 and 2017 were $7,800]and $7,500, respectively.

7. SUBSEQUENT EVENTS

In August 2018, the Company issued a total of 37,500 shares of common stock to one consultant as payment for services and recorded expenses of $64,125 based on the fair value of the Company’s common stock at the issuance date.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

As used in this discussion and analysis and elsewhere in this Quarterly Report, the “Company”, “we”, “us” or “our” refer to Vitality Biopharma, Inc., a Nevada corporation.

Cautionary Statement

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Unaudited Condensed Financial Statements and the related notes thereto contained in Part I, Item 1 of this Quarterly Report. The information contained in this Quarterly Report on Form 10-Q is not a complete description of our business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the fiscal year ended March 31, 2018 filed on June 28, 2018, and the related audited financial statements and notes included therein.

Certain statements made in this Quarterly Report on Form 10-Q constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our or our industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These risks and uncertainties include: general economic and financial market conditions; our ability to obtain additional financing as necessary; our ability to continue operating as a going concern; any adverse occurrence with respect to our business or; results of our research and development activities that are less positive than we expect ; our ability to bring our intended products to market; market demand for our intended products; shifts in industry capacity; product development or other initiatives by our competitors; fluctuations in the availability of raw materials and costs associated with growing raw materials for our intended products; poor growing conditions for the stevia plant; other factors beyond our control; and the other risks described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on June 28, 2018.

Although we believe that the expectations and assumptions reflected in the forward-looking statements we make are reasonable, we cannot guarantee future results, levels of activity or performance. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those expressed by any forward-looking statements. As a result, readers should not place undue reliance on any of the forward-looking statements we make in this report. Forward-looking statements speak only as of the date on which they are made. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Company Overview

Vitality Biopharma is unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders.

We hold exclusive worldwide intellectual property and commercialization rights to a new class of cannabinoid pharmaceutical candidates known as cannabosides. This class of compounds includes VBX-100, a prodrug of tetrahydrocannabinol (THC), which enables targeted delivery of THC to the gastrointestinal tract without any resulting drug psychoactivity or intoxication.

Cannabosides are cannabinoid glycoside “prodrugs,” which means that they are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug. Because there often already exists independent verification of the active drug’s safety and efficacy, as is the case with THC, which has been FDA-approved as a pharmaceutical since 1985, prodrugs may receive regulatory and marketing approvals more quickly than others. At the same time, a prodrug can have many commercial advantages, including that they can be proprietary and patentable compositions of matter, unlike cannabinoids themselves, or older pharmaceutical formulations where patent protection has already expired.

Our most advanced drug candidate, VBX-100, is a prodrug of THC, which was first approved as a pharmaceutical by the FDA in 1985 under the brand name MARINOL^TM and that is known by the generic drug name of dronabinol. VBX-100 enables targeting or restriction of THC to the gastrointestinal tract, thereby eliminating or avoiding the psychoactive or intoxicating effects that occur when THC enters the bloodstream and brain. VBX-100 may enable more widespread use of THC for treatment of gastrointestinal conditions as well as its use in many patient populations for whom treatment today with THC is not generally recommended, including children, patients who are pregnant or breastfeeding, and patients with a history or high risk of mental illness.

VBX-100 is being developed for treatment of inflammatory bowel disease (IBD), C. difficile-associated diarrhea and colitis (CDAC), irritable bowel syndrome (IBS), and narcotic bowel syndrome (NBS), a severe form of opiate-induced abdominal pain.

For IBD, which includes Crohn’s disease and ulcerative colitis, there have been independently-conducted preclinical and clinical studies that have demonstrated the benefit of cannabinoids. Independently-run retrospective clinical studies have found that in 56 patients who used cannabinoids with IBD that 83.9% of patients reported improvement in abdominal pain, and 76.8% of patients reported improvement in abdominal cramping. In addition, in a prospective trial that was independently-managed and placebo-controlled, it was found that 45% of Crohn’s disease patients achieved remission after 8 weeks of treatment. Patients reported improvements in sleep and appetite with no significant side effects and some patients were able to eliminate use of corticosteroids and opiate pain medications. Patients experienced benefits with cannabis treatment despite being non-responders to conventional therapies, such as corticosteroids, immunomodulators, and TNF-alpha inhibitors. VBX-100 may enable treatment of drug-resistant forms of IBD without any psychoactivity and also without the adverse effects of alternative IBD therapies, many of which today suppress the immune system throughout the body and can increase the risk of infections or cancer.

A key part of our strategy will be to take advantage of a more efficient Food & Drug Administration (FDA) review and approval process that is available for prodrugs, which reduces the need for large and expensive clinical trials. Expedited regulatory processes may be available for our cannabosides because in the U.S. and internationally there have already been many independent preclinical and clinical studies completed using THC, and so existing clinical data may be submitted to drug regulatory agencies as supporting evidence of our compounds’ safety.

We aim to develop and approve our pharmaceutical candidates using a low-risk regulatory strategy that is available for prodrugs, and to amplify the benefits that have been seen in independent, early-stage clinical trials and preclinical studies describing the use of cannabinoids for treatment of neurological and inflammatory conditions. Our focus is especially on eliminating well known side effects of existing therapies, and on treating conditions known to involve the endocannabinoid system and the gastrointestinal tract.

Our primary operations are based in Yuba City, California, where we originally developed our proprietary bioprocessing methods. The Company’s research and development facilities include laboratories and a manufacturing suite that will be used for pharmaceutical-grade production of drug material for clinical trials. These facilities and the company’s operations involving handling and use of controlled substances have been registered with and authorized by the Drug Enforcement Administration (DEA) as well as the Research Advisory Panel of California, a part of the State of California’s Department of Justice.

Product Pipeline

We have produced more than 25 novel cannabosides so far and have patent applications that include composition of matter claims for prodrugs of cannabinoids that have been studied extensively in clinical trials worldwide, including THC and cannabidiol (CBD). Upon successful patent prosecution, protection would extend until 2035 and be available in all major markets worldwide. In addition, we have filed patent applications that seek to protect more broad claims on novel vanilloid glycoside compounds that target TRPV receptors for mediating pain relief, methods of use for TRPV1 agonists to effect neural repair, and based on findings in early 2017, for drug compositions and methods to use cannabinoids to treat gut dysbiosis and drug-resistant C.difficile infections, which colonize the large intestine.

Cannaboside prodrugs may deliver a variety of benefits over existing cannabinoid therapies, including:

	1.	Administration of cannabinoids in a convenient oral formulation;

	2.	Targeted delivery of cannabinoids without any psychoactivity or intoxication, which can be achieved through gut-restricted prodrugs that are released in the colon or large intestine and that avoid entry into the bloodstream or brain;

	3.	Improved stability, preventing degradation or drug metabolism, enabling larger and more reliable doses of cannabinoids to be delivered to the site of disease; and

	4.	Delayed release, enabling long-lasting and overnight relief for patients, rather than having to administer treatment repeatedly throughout the day and requiring additional sleep aids.

VBX-100 is an oral cannaboside and a prodrug of THC, or dronabinol, which was first approved by the US FDA in 1985. MARINOL^TM is an approved version of dronabinol that is indicated for treatment of anorexia and chemotherapy-induced nausea and vomiting. VBX-100 is targeted or restricted to the gastrointestinal tract, so it could eliminate the psychoactive effects of THC, which may enable widespread adult use of THC for treatment of gastrointestinal conditions as well as use in patient populations where use of THC is currently limited or avoided, including for treatment of pediatric conditions or for treatment of patients with a history of mental illness. VBX-100 is intended primarily for acute or short-term use, such as for treatment regimens to induce remission of disease flares that occur in pediatric Crohn’s disease or ulcerative colitis, or for use to relieve severe abdominal pain while narcotic bowel syndrome patients reduce or eliminate use of opioid painkillers.

VBX-210 is an oral cannaboside formulation being investigated in preclinical studies for treatment of gastrointestinal conditions. VBX-210 is intended primarily for chronic or long-term use (greater than 6 months per year), including long-term management of irritable bowel syndrome, chronic pain, prevention of colorectal cancer, or maintaining remission of inflammatory bowel disease. We are developing additional cannabinoid product formulations that are intended to provide relief of refractory pain in patients using cannabinoids as an alternative to opioid painkillers, as well as formulations intended to improve the symptoms of autism spectrum disorder.

Products	Treatment Indications	Status

VBX-100	Inflammatory Bowel Disease (inducing remission), Irritable Bowel Syndrome C.difficile-associated Diarrhea and Colitis, Narcotic Bowel Syndrome	Phase 1 Trial to be initiated in 2^ndHalf of 2018

VBX-210	Irritable Bowel Syndrome, Chronic Pain, Inflammatory Bowel Disease (maintaining remission), Colorectal Cancer	Preclinical

Additional Cannabinoid Formulations	Refractory Pain, Autism Spectrum Disorder	Discovery

For each of the pharmaceutical candidates in our pipeline, the active cannabinoid pharmaceutical agents have been independently approved by regulatory bodies and there is extensive clinical data already available related to drug safety and effectiveness. Because of this, we will in general benefit from the increased familiarity of clinical investigators and regulators with these compounds, which may enable abbreviated paths towards clinical testing and eventual approval of our pharmaceutical products.

Our Operations

We believe that our long-term commercial success and profit potential depends in large part on our ability to develop and advance proprietary cannabinoid prodrugs that are strongly differentiated from both medical cannabis and existing cannabinoid drugs, and to do this more quickly, efficiently and effectively than our competitors. Another critical factor that will determine our success is our ability to obtain and enforce patents, maintain protection of trade secrets, and operate our business without infringing the proprietary rights of third parties. As a result, we are dedicated to the continued development and protection of our intellectual property portfolio.

We developed internally and hold exclusive worldwide intellectual property rights related to two U.S. patent applications filed in September and October 2015, titled “Cannabinoid Glycoside Prodrugs and Methods of Synthesis.” In September 2016, an expanded international application was filed under the Patent Cooperation Treaty system, which includes 79 patent claims to almost 200 individual compounds, including but not limited to prodrugs of THC and CBD. In March and April 2018, applications were filed for national and regional prosecution in major pharmaceutical markets worldwide including the U.S., Europe, Japan, Canada, Mexico, Australia, New Zealand, China, and Brazil. For more information, see the “Intellectual Property” section below.

Short Term Development Targets

We plan to complete all necessary preclinical studies for VBX-100 and to initiate a Phase 1 clinical trial in the second half of 2018. This first-in-man clinical study will focus primarily on evaluating the clinical pharmacokinetics, safety, and tolerability of VBX-100 in healthy volunteers. Additional endpoints may be analyzed to examine the effects of VBX-100 on GI motility, intestinal permeability, and on the human microbiome. The Phase 1 first-in-human trial is intended to provide safety data sufficient for us to initiate multiple Phase 2 proof-of-concept clinical studies in 2019, including for treatment of IBD and IBS. We plan to conduct additional preclinical studies on VBX-100 and our other pharmaceutical candidates, as well as sponsor observational clinical studies of cannabinoids for new treatment indications including prevention of colorectal cancer, treatment of refractory pain (opioid substitution therapy), and treatment of autism spectrum disorder.

Short-term development targets include:

●	Complete remaining preclinical studies for VBX-100 including conduct of GLP toxicology studies

●	Obtain regulatory approval from FDA for initiation of a Phase 1 study of VBX-100

●	Complete additional preclinical efficacy studies of VBX-100 including for treatment of autism, visceral pain, and colorectal cancer

●	Through collaborators, initiation of one or more observational clinical studies of systemic cannabinoid therapies, including for treatment of autism spectrum disorder and for treatment of refractory pain (substitution therapy for opioid painkillers)

Additional Operations

Our glycosylation technology was originally developed in order to improve the taste and yield of stevia sweeteners derived from the stevia plant. We have an intellectual property portfolio related to stevia, as well as commercial operations related to the manufacture and sale of research products that commenced in 2014. We intend to sustain these operations and technologies in a manner that is cash-flow neutral or better and to commercialize the primarily through new out-licensing arrangements or strategic partnerships.

Results of Operations

Three Months Ended June 30, 2018 and June 30, 2017

Our net loss during the three months ended June 30, 2018 was $1,135,219 compared to a net loss of $1,106,353 for the three months ended June 30, 2017. During the three months ended June 30, 2018, we generated $26,328 in revenue and $580 in gross profit, compared to $27,043 in revenue and $6,557 in gross profit for the 2017 period. Our revenue in each of the periods presented was earned from the sale of research diagnostic testing kits and chemicals. We expect such sales to continue at approximately the rate during the 2018 period.

During the three months ended June 30, 2018, we incurred general and administrative expenses in the aggregate amount of $523,184 compared to $673,789 incurred during the three months ended June 30, 2017 (a decrease of $150,605). General and administrative expenses generally include corporate overhead, salaries and other compensation costs, financial and administrative contracted services, marketing, consulting costs and travel expenses. A significant portion of these costs are related to the development of our organizational capabilities as a biotechnology company, including costs such as legal and advisory fees related to intellectual property development. The majority of the decrease in general and administrative costs in the period relates to professional fees which decreased to $43,135 in the period ending June 30, 2018, as compared to $129,254 in the period ending June 30, 2017.

In addition, during the three months ended June 30, 2018, we incurred research and development costs of $587,422, compared to $407,009 during the three months ended June 30, 2017 (an increase of $180,413). This increase resulted from increased laboratory and consulting expenses during the 2018 period.

During the three months ended June 30, 2018, we incurred related party rent and other costs totaling $7,800 compared to $7,500 incurred during the three months ended June 30, 2017.

This resulted in a loss from operations of $1,117,826 during the three months ended June 30, 2018 compared to a loss from operations of $1,081,741 during the three months ended June 30, 2017.

During the three months ended June 30, 2018, we recorded total net other expense in the amount of $17,393, compared to total net other expense recorded during the three months ended June 30, 2017 in the amount of $24,612. During the three months ended June 30, 2018, we recorded an expense related to the change in fair value of derivatives of $17,393, compared to an expense of $24,612 during the 2017 quarter. This resulted in a net loss of $1,135,219 during the three months ended June 30, 2018 compared to a net loss of $1,106,353 during the three months ended June 30, 2017.

The net loss during the three months ended June 30, 2018 compared to the net loss for the three months ended June 30, 2017 is attributable primarily to the higher research and development costs in the 2018 period.

Liquidity and Capital Resources

As of June 30, 2018, we had total current assets of $182,706, which was comprised mainly of cash of $173,037. Our total current liabilities as of June 30, 2018 were $518,225 and consisted of accounts payable and accrued liabilities of $347,790 and derivative liability of $170,435. The derivative liability is a non-cash item related to certain of our outstanding warrants as of June 30, 2018. As a result, on June 30, 2018, we had working capital deficit of $335,519.

We have not yet received significant revenues from sales of products or services, and have recurring losses from operations. We have incurred losses since inception resulting in stockholders’ deficit of $335,519 as of June 30, 2018, and further losses are anticipated in the development of our business. These factors raise substantial doubt about our ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s March 31, 2018 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Our financial statements included in this report have been prepared on a going concern basis, which assumes that we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. The continuation of our Company as a going concern is dependent upon our Company attaining and maintaining profitable operations and raising additional capital. The financial statements included in this report do not include any adjustments relating to the recovery and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should our Company discontinue operations.

We estimate that we will have sufficient funds to operate the business for the six months after June 30, 2018. These estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.

We do not have any firm commitments for future capital. Significant additional financing will be required to fund our planned operations in future periods, including research and development activities relating to our principal product candidate, seeking regulatory approval of that or any other product candidate we may choose to develop, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We do not presently have, nor do we expect in the near future to have, revenue to fund our business from our operations, and will need to obtain significant funding from external sources. We may seek to raise such funding from a variety of sources. If we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, we may not be able to obtain additional financing from any of these sources on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

Net Cash Used in Operating Activities

We have not generated positive cash flows from operating activities. For the three months ended June 30, 2018, net cash used in operating activities was $483,253 compared to net cash used in operating activities of $622,164 for the three months ended June 30, 2017. This decrease was primarily attributable to an increase in accounts payable. Net cash used in operating activities during the three months ended June 30, 2018 consisted primarily of a net loss of $1,135,219, offset by $474,426 related to stock-based compensation and change in fair value of derivative liability of $17,393. Net cash used in operating activities during the three months ended June 30, 2017 consisted primarily of a net loss of $1,106,353, offset by $545,124 related to stock-based compensation and change in fair value of derivative liability of $24,612.

Net Cash Used in Investing Activities

During the three months ended June 30, 2018 and June 30, 2017, no net cash was used in or provided by investing activities.

Net Cash Provided By Financing Activities

During the three months ended June 30, 2018 and June 30, 2017, no net cash was used in or provided by financing activities.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that would be material to stockholders.

Critical Accounting Policies

Our financial statements and accompanying notes included in this report have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) applied on a consistent basis. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from the estimates made by management.

We believe the following critical accounting policies require us to make significant judgments and estimates in the preparation of our consolidated financial statements included in this report:

Use of Estimates and Assumptions

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumption by management include, among others, the fair value of shares issued for services, the fair value of options and warrants, and assumptions used in the valuation of our outstanding derivative liabilities.

Stock-Based Compensation

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the Financial Accounting Standards Board (FASB”) Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

Derivative Financial Instruments

We evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, we use a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2018 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Recent Accounting Pronouncements

Please refer to Footnote 1 of the accompanying financial statements for management’s discussion of recent accounting pronouncements

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not Applicable.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive and financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. Based on this evaluation, our principal executive and financial officer concluded that as of June 30, 2018, these disclosure controls and procedures were not effective to ensure that the information required to be disclosed by our Company in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (“SEC”), including that such information is accumulated and communicated to our management, including our principal executive and financial officer, as appropriate to allow timely decisions regarding required disclosures .. The conclusion that our disclosure controls and procedures were not effective was due to the presence of material weaknesses in our internal control over financial reporting, as that term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, as previously disclosed in Item 9A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2018. In light of the material weaknesses identified by management, we performed additional analyses and procedures in order to conclude that our condensed financial statements for the interim period ended June 30, 2018 are fairly presented, in all material respects, in accordance with GAAP.

Description of Material Weaknesses and Management’s Remediation Initiatives

As of the date of this report, our remediation efforts continue related to each of the material weaknesses that we have identified in our internal control over financial reporting and additional time and resources will be required in order to fully address these material weaknesses. We have not been able to complete all actions necessary and test the remediated controls in a manner that would enable us to conclude that such controls are effective. We are committed to implementing the necessary controls to remediate the material weaknesses described below, as and when resources permit. These material weaknesses will not be considered remediated until (1) the new processes are designed, appropriately controlled and implemented for a sufficient period of time and (2) we have sufficient evidence that the new processes and related controls are operating effectively. The following is a list of the material weaknesses identified by management as of June 30, 2018:

Insufficient segregation of duties in our finance and accounting functions due to limited personnel. During the three months ended June 30, 2018, we internally performed all aspects of our financial reporting process, including, but not limited to, access to the underlying accounting records and systems, the ability to post and record journal entries and responsibility for the preparation of the financial statements. Due to the fact that these duties were often performed by the same person, there was a lack of review over the financial reporting process that might result in a failure to detect errors in spreadsheets, calculations, or assumptions used to compile the financial statements and related disclosures as filed with the SEC. This could result in a material misstatement to our interim or annual financial statements that would not be prevented or detected.

Changes in Internal Control over Financial Reporting

In June 2018, we determined that Dr. Dhillon was an independent director within the meaning of applicable Nasdaq Listing Rules, resulting in a majority of our board of directors being independent directors.

We are currently considering adding additional independent members to our board of directors and adding accounting personnel to our staff in connection with the ongoing efforts to remediate the material weaknesses described above, but no specific progress has been made on these goals or other remediation efforts during the three months ended June 30, 2018. As a result, other than the change described here and the ongoing remediation efforts identified above, there were no changes in our internal control over financial reporting during the three months ended June 30, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Internal Control

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple errors. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. In addition, projections of any evaluation of effectiveness to future periods are subject to risks that controls that are effective at one date may subsequently become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may deteriorate.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not currently a party to and our properties are not currently the subject of any material pending legal proceedings the adverse outcome of which, individually or in the aggregate, would be expected to have a material adverse effect on our financial position or results of operations.

Item 1A. Risk Factors

Please refer to the risks described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on June 28, 2018.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 6. Exhibits

Exhibit Number		Description of Exhibit

3.1.1		Articles of Incorporation of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.1.2		Articles of Merger, effective October 10, 2011 (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.1.3		Certificate of Change, effective October 10, 2011 (Incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.2.1		Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.2 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.2.2		Certificate of Amendment of Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on February 7, 2012.)

31.1		Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

32.1		Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002†

101.INS		XBRL Instance Document *

101.SCH		XBRL Taxonomy Extension Schema Document *

101.CAL		XBRL Taxonomy Extension Calculation Linkbase *

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document *

101.LAB		XBRL Taxonomy Extension Label Linkbase Document *

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document *

† Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VITALITY BIOPHARMA, INC.

By:	/s/ Robert Brooke
	Robert Brooke
	Chief Executive Officer
	(Principal Executive Officer and Principal Financial and Accounting Officer)

Date: August 14, 2018

EXHIBIT INDEX

Exhibit Number		Description of Exhibit

3.1.1		Articles of Incorporation of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.1.2		Articles of Merger, effective October 10, 2011 (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.1.3		Certificate of Change, effective October 10, 2011 (Incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.2.1		Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.2 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.2.2		Certificate of Amendment of Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on February 7, 2012.)

31.1		Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

32.1		Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002†

101.INS		XBRL Instance Document *

101.SCH		XBRL Taxonomy Extension Schema Document *

101.CAL		XBRL Taxonomy Extension Calculation Linkbase *

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document *

101.LAB		XBRL Taxonomy Extension Label Linkbase Document *

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document *

† Furnished herewith.

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION

I, Robert Brooke , certify that:

	1.	I have reviewed this report on Form 10-Q for the quarterly period ended June 30, 2018 of Vitality Biopharma, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2018

Name:	/s/ Robert Brooke
By:	Robert Brooke
Title:	Chief Executive Officer
	(Principal Executive Officer and Principal Financial and Accounting Officer)

EX-32.1 3 ex32-1.htm

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Robert Brooke, the Chief Executive Officer of Vitality Biopharma, Inc. (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q for the period ended June 30, 2018, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.

/s/ Robert Brooke
Robert Brooke
Chief Executive Officer
(Principal Executive Officer and
Principal Financial and Accounting Officer)

Date: August 14, 2018

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

EX-101.INS 4 vbio-20180630.xml XBRL INSTANCE FILE 0001438943 2018-04-01 2018-06-30 0001438943 2018-06-30 0001438943 us-gaap:WarrantMember 2017-04-01 2017-06-30 0001438943 us-gaap:WarrantMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsOneMember 2018-06-30 0001438943 VBIO:StockOptionsTwoMember 2018-06-30 0001438943 VBIO:StockOptionsThreeMember 2018-06-30 0001438943 VBIO:StockOptionsFourMember 2018-06-30 0001438943 VBIO:StockOptionsFiveMember 2018-06-30 0001438943 VBIO:StockOptionsSixMember 2018-06-30 0001438943 VBIO:StockOptionsFiveMember srt:MaximumMember 2018-06-30 0001438943 VBIO:StockOptionsFiveMember srt:MinimumMember 2018-06-30 0001438943 VBIO:StockOptionsOneMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsTwoMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsThreeMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsFourMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsFiveMember srt:MaximumMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsFiveMember srt:MinimumMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsSixMember srt:MinimumMember 2018-06-30 0001438943 VBIO:StockOptionsSixMember srt:MaximumMember 2018-06-30 0001438943 VBIO:StockOptionsSixMember srt:MinimumMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsSixMember srt:MaximumMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsSevenMember 2018-06-30 0001438943 VBIO:StockOptionsSevenMember srt:MinimumMember 2018-06-30 0001438943 VBIO:StockOptionsSevenMember srt:MaximumMember 2018-06-30 0001438943 VBIO:StockOptionsSevenMember srt:MinimumMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsSevenMember srt:MaximumMember 2018-04-01 2018-06-30 0001438943 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001438943 2018-03-31 0001438943 us-gaap:CommonStockMember 2018-03-31 0001438943 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001438943 us-gaap:RetainedEarningsMember 2018-03-31 0001438943 us-gaap:RestrictedStockMember 2018-03-31 0001438943 2016-08-19 0001438943 2016-08-18 2016-08-19 0001438943 VBIO:CarlsonLeaseMember 2012-04-01 2012-04-23 0001438943 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2017-04-01 2018-03-31 0001438943 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2017-04-01 2018-03-31 0001438943 us-gaap:MeasurementInputPriceVolatilityMember 2017-04-01 2018-03-31 0001438943 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2017-04-01 2018-03-31 0001438943 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2017-04-01 2018-03-31 0001438943 us-gaap:MeasurementInputExpectedDividendRateMember 2017-04-01 2018-03-31 0001438943 us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-04-01 2018-06-30 0001438943 us-gaap:MeasurementInputPriceVolatilityMember 2018-04-01 2018-06-30 0001438943 us-gaap:MeasurementInputExpectedDividendRateMember 2018-04-01 2018-06-30 0001438943 VBIO:StockOptionsFourMember srt:MinimumMember 2018-06-30 0001438943 VBIO:StockOptionsFourMember srt:MaximumMember 2018-06-30 0001438943 2016-05-31 0001438943 VBIO:OneConsultantsMember 2018-02-01 2018-02-28 0001438943 2017-04-01 2017-06-30 0001438943 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001438943 us-gaap:CommonStockMember 2018-06-30 0001438943 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001438943 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001438943 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001438943 us-gaap:RetainedEarningsMember 2018-06-30 0001438943 2017-03-31 0001438943 2017-06-30 0001438943 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001438943 2017-04-01 2018-03-31 0001438943 us-gaap:MeasurementInputExpectedTermMember 2018-04-01 2018-06-30 0001438943 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0001438943 us-gaap:RestrictedStockMember 2018-06-30 0001438943 2018-08-13 xbrli:pure iso4217:USD xbrli:shares xbrli:shares iso4217:USD false --03-31 2018-06-30 10-Q Smaller Reporting Company Vitality Biopharma, Inc.

347790

200475

6611

13843

321420

182706

675791

173037

656290

1152766

530602

-483253

-622164

0.001

1000000000

525000000

24312647

24275147

24312647

24275147

24112

24075

147315

-66913

-12500

-7232

6134

518225

353517

-1135219

-1106353

-1135219

24275147

24312647

-335519

322274

24075

22343135

-22044936

24112

22820524

-23180155

37500

2650000

49125

64125

49088

VBIO Q1

-23180155

-22044936

182706

675791

3058

170435

153042

580

6557

26328

27043

1118406

1088298

7800

7500

587422

407009

523184

673789

-1117826

-1081741

-17393

-24612

24290806

22255290

-0.05

-17393

-24612

0001438943

49125

100000

2. DERIVATIVE LIABILITY   In May 2015, the Company issued certain warrants which included an anti-dilution provision that allows for the automatic reset of the exercise price of the warrants upon future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants. In addition, the Company determined that the warrants can be settled for cash at the holders’ option in a future fundamental transaction, as defined. As a result of the anti-dilution and fundamental transaction provisions, the Company determined that the conversion feature of the warrants should be separated from the host contract, be recognized as a derivative liability, and re-measured at each reporting period with the change in value reported in the statement of operations.   At March 31, 2018, the balance of the derivative liabilities was $153,042. During the three months ended June 30, 2018, the Company recorded an increase in derivative liability of $17,393. At June 30, 2018, the balance of the derivative liabilities was $170,435.   At June 30, 2018 and March 31, 2018, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">March 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Conversion feature:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 66%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">2.52</td> <td style="width: 1%; line-height: 107%">%</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">1.73-2.27</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">119</td> <td style="line-height: 107%">%</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">121</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected life (in years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2 years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">.25 to 2.15 years</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Fair Value:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Conversion feature</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">170,435</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">153,042</td> <td style="line-height: 107%"> </td></tr> </table>   The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.

3. STOCKHOLDERS’ EQUITY (DEFICIENCY)   Common stock issued to employees with vesting terms   The Company has issued shares of common stock to employees and directors that vest over time. The fair value of these stock awards are based on the market price of the Company’s common stock on the dates granted, and are amortized over vesting terms ranging up to three years.   During the three months ended June 30, 2018, we recorded expense related to the fair value of stock awards that vested of $106,881. At June 30, 2018, the amount of unvested compensation related to these awards is approximately $240,000, and will be recorded as expense over 1 year.   Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board. In the event a recipient’s employment or service with the Company terminates, any or all of the shares of common stock held by such recipient that have not vested as of the date of termination under the terms of the restricted stock agreement are forfeited to the Company in accordance with such restricted grant agreement.   The following table summarizes restricted common stock activity:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Shares</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; line-height: 107%">Non-vested shares, April 1, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">918,085</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Vested</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-vested shares, June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">918,085</td> <td style="line-height: 107%"> </td></tr> </table>   Common stock issued for services   During the three months ended June 30, 2018, the Company issued a total of 37,500 shares of common stock to one consultant as payment for services and recorded expenses of $49,125 based on the fair value of the Company’s common stock at the issuance date.

4. STOCK OPTIONS   A summary of the Company’s stock option activity during the three months ended June 30, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Exercise Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%">Balance outstanding at March 31, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">3,316,710</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">1.40</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Cancelled</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Balance outstanding at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,316,710</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.40</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Balance exercisable at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,255,648</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.22</td> <td style="line-height: 107%"> </td></tr> </table>   A summary of the Company’s stock options outstanding and exercisable as of June 30, 2017 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Grant- date Stock Price</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Options Outstanding, June 30, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">1,664,542</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">0.50</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">0.50</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">128,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.96</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.96</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">130,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.00</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">10.00</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">477,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.50-1.81</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.50</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">747,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.00 – 2.79</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.00 – 2.79  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">123,334</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3.10 – 3.80</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3.10 – 3.80  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">45,834</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">4.00 – 4.70</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">4.00 – 4.70  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,316,710</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Options Exercisable, June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,259,980</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.50</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.50</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">101,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.96</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.96</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">130,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.00</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">10.00</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">147,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.50-1.81</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.50-1.81  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">447,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.00 – 2.79</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.00 – 2.79  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">123,334</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3.10 – 3.80</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3.10 – 3.80  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">45,834</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">4.00 – 4.70</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">4.00 – 4.70  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,255,648</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> </table>   During the three months ended June 30, 2018, we expensed total stock-based compensation related to stock options of $321,420, and the remaining unamortized cost of the outstanding stock-based awards at June 30, 2018 was approximately $799,000. This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years. At June 30, 2018, the 3,316,710 outstanding stock options had an intrinsic value of approximately $2,100,000.

5. WARRANTS   At June 30, 2018, warrants to purchase common shares were outstanding as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%">Balance at March 31, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">1,164,422</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">2.19</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(29,419</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">4.25</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Balance outstanding and exercisable at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,135,003</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2.19</td> <td style="line-height: 107%"> </td></tr> </table>

6. RELATED PARTY OBLIGATIONS   On April 23, 2012, the Company entered into a lease agreement with One World Ranches, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Company’s Board of Directors, and his wife, to rent the space being used as the Company’s principal office and laboratory facility. The original term of the lease was from May 1, 2012 to May 1, 2017. In May 2017, the Company extended the lease through May 1, 2020. Our rent payments thereunder were $2,300 per month until May 1, 2017 and increased to $2,600 per month on May 1, 2017. Aggregate payments under the lease for the three months ended June 30, 2018 and 2017 were $7,800]and $7,500, respectively.

8. SUBSEQUENT EVENTS   In February 2018, the Company issued a total of 37,500 shares of common stock to one consultant as payment for services and recorded expenses of $64,125 based on the fair value of the Company’s common stock at the issuance date.

Going Concern   The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended June 30, 2018, the Company incurred a net loss of $1,135,219 and used cash in operating activities of $483,253. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.   The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that as of June 30, 2018 we have sufficient funds to operate the business for the next [6] months. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, licensing or acquiring new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.   We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

Use of Estimates   The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.

Financial Assets and Liabilities Measured at Fair Value   The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify; line-height: 107%">Level 1</td> <td style="width: 1%; text-align: justify; line-height: 107%"> </td> <td style="width: 93%; text-align: justify; line-height: 107%">Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">Level 2</td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">Level 3</td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">Unobservable inputs based on the Company’s assumptions.</td></tr> </table>   The fair value of the derivative liabilities of $170,435 and $153,042 at June 30, 2018 and March 31, 2018, respectively, were valued using Level 2 inputs.   The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Derivative Financial Instruments   The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2018, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.

Stock-Based Compensation   The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.   The Company periodically issues unvested (“restricted”) shares of its common stock to employees as equity incentives. The Company’s restricted stock vests upon the satisfaction of a recipient’s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company’s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period.

Basic and Diluted Loss Per Share   Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three months ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 107%">Options</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">3,316,710</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">2,820,489</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,135,003</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">372,421</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,451,713</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,192,910</td> <td style="line-height: 107%"> </td></tr> </table>

Research and Development   Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred.

Recent Accounting Pronouncements   In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.   In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features. ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company plans to adopt ASU 2017-11 on April 1, 2019. The adoption of ASU 2017-11 is not expected to have an impact on the Company’s financial statements and related disclosures because the conversion feature of the Company’s warrants have features other than down round provisions that require the current accounting treatment and classification.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three months ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 107%">Options</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">3,316,710</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">2,820,489</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,135,003</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">372,421</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,451,713</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,192,910</td> <td style="line-height: 107%"> </td></tr> </table>

At June 30, 2018 and March 31, 2018, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">March 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Conversion feature:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 66%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">2.52</td> <td style="width: 1%; line-height: 107%">%</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">1.73-2.27</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">119</td> <td style="line-height: 107%">%</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">121</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected life (in years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2 years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">.25 to 2.15 years</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Fair Value:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Conversion feature</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">170,435</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">153,042</td> <td style="line-height: 107%"> </td></tr> </table>

The following table summarizes restricted common stock activity:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Shares</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; line-height: 107%">Non-vested shares, April 1, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">918,085</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Vested</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-vested shares, June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">918,085</td> <td style="line-height: 107%"> </td></tr> </table>

A summary of the Company’s stock option activity during the three months ended June 30, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Exercise Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%">Balance outstanding at March 31, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">3,316,710</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">1.40</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Cancelled</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Balance outstanding at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,316,710</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.40</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Balance exercisable at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,255,648</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.22</td> <td style="line-height: 107%"> </td></tr> </table>

A summary of the Company’s stock options outstanding and exercisable as of June 30, 2017 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Grant- date Stock Price</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Options Outstanding, June 30, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">1,664,542</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">0.50</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">0.50</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">128,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.96</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.96</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">130,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.00</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">10.00</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">477,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.50-1.81</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.50</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">747,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.00 – 2.79</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.00 – 2.79  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">123,334</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3.10 – 3.80</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3.10 – 3.80  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">45,834</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">4.00 – 4.70</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">4.00 – 4.70  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,316,710</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Options Exercisable, June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,259,980</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.50</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.50</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">101,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.96</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.96</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">130,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.00</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">10.00</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">147,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.50-1.81</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.50-1.81  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">447,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.00 – 2.79</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.00 – 2.79  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">123,334</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3.10 – 3.80</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3.10 – 3.80  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">45,834</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">4.00 – 4.70</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">4.00 – 4.70  </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,255,648</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> </table>

At June 30, 2018, warrants to purchase common shares were outstanding as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%">Balance at March 31, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">1,164,422</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">2.19</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(29,419</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">4.25</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Balance outstanding and exercisable at June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,135,003</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2.19</td> <td style="line-height: 107%"> </td></tr> </table>

2600 -2600

7950000

2.19

P1Y

240000

918085

1135003

1164422

-29419 4.25 The Carlson Lease began on May 1, 2012 and was extended from May 1, 2017 to May 1, 2020.

2300

2017-05-01

7800

1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. The Company’s fiscal year end is March 31.   In 2015, the Company developed a new class of cannabinoids known as cannabosides, which were discovered through application of the Company’s proprietary enzymatic bioprocessing technologies originally developed for stevia sweeteners. In 2016, the Company received approvals from the U.S. Drug Enforcement Administration (the “DEA”) and the State of California to initiate studies and manufacturing scale-up at its research and development facilities in order to develop cannabosides.   In May 2016, we received shareholder and board approval for a name change to Vitality Biopharma, Inc., an exchange of one (1) share of the Company’s common stock for each 10 shares of common stock outstanding or exercisable under any outstanding warrants or option agreements, and an increase in the number of shares of authorized common stock from 525,000,000 to 1,000,000,000. These corporate changes became effective on July 20, 2016.   Going Concern   The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended June 30, 2018, the Company incurred a net loss of $1,135,219 and used cash in operating activities of $483,253. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.   The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that as of June 30, 2018 we have sufficient funds to operate the business for the next [6] months. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, licensing or acquiring new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.   We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.   Basis of Presentation of Unaudited Condensed Financial Information   The unaudited condensed financial statements of the Company for the three months ended June 30, 2018 and 2017 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2018 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2018 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 28, 2018. These financial statements should be read in conjunction with that report.   Use of Estimates   The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.   Financial Assets and Liabilities Measured at Fair Value   The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify; line-height: 107%">Level 1</td> <td style="width: 1%; text-align: justify; line-height: 107%"> </td> <td style="width: 93%; text-align: justify; line-height: 107%">Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">Level 2</td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">Level 3</td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">Unobservable inputs based on the Company’s assumptions.</td></tr> </table>   The fair value of the derivative liabilities of $170,435 and $153,042 at June 30, 2018 and March 31, 2018, respectively, were valued using Level 2 inputs.   The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.   Derivative Financial Instruments   The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2018, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.   Stock-Based Compensation   The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.   The Company periodically issues unvested (“restricted”) shares of its common stock to employees as equity incentives. The Company’s restricted stock vests upon the satisfaction of a recipient’s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company’s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period.   Basic and Diluted Loss Per Share   Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three months ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 107%">Options</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">3,316,710</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">2,820,489</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,135,003</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">372,421</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,451,713</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,192,910</td> <td style="line-height: 107%"> </td></tr> </table>   Research and Development   Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred.   Recent Accounting Pronouncements   In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.   In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features. ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company plans to adopt ASU 2017-11 on April 1, 2019. The adoption of ASU 2017-11 is not expected to have an impact on the Company’s financial statements and related disclosures because the conversion feature of the Company’s warrants have features other than down round provisions that require the current accounting treatment and classification.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

321420

342540

106881

25748

20486

106881 102584

7. COMMITMENTS   On August 19, 2016, we filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. We received subpoenas to produce documents dated December 14, 2016, and January 23, 2017, and a further subpoena for testimony and any supplemental production of documents dated June 5, 2017. The document requests were primarily in connection with this matter. We have complied with all document requests and the Company’s CEO will provide testimony when the SEC schedules such testimony, which we believe will be sometime before the end of September 2018.

2600

In May 2016, we received shareholder and board approval for a name change to Vitality Biopharma, Inc., an exchange of one (1) share of the Company's common stock for each 10 shares of common stock outstanding or exercisable under any outstanding warrants or option agreements, and an increase in the number of shares of authorized common stock from 525,000,000 to 1,000,000,000. These corporate changes became effective on July 20, 2016.

170435

153042

4451713

372421

1135003

3316710

3192910

2820489

17393

0.0173 0.0227 1.21 0.00 0.0252 1.19 0.00 P2M30D P2Y1M24D P2Y

0.50

0.96

10.00

1.50

2.79

2.00

3.10

3.80

4.00

4.70

799000

P2Y

3316710

1664542

128000

130000

477500

747500

123334

45834

3316710

2100000

2255648

1259980

101500

130000

147500

447500

123334

45834

1.40

1.22

0.50

0.96

1.00

2.79

2.00

3.10

3.80

4.00

4.70

1.50

1.81

0.50

0.96

1.00

2.79

2.00

3.10

3.80

4.00

4.70

1.50

1.81

0.50 0.96 10.00 2.79 2.00 3.10 3.80 4.00 4.70 1.50 1.81

22820524

22343135

-483253

-622164

106881

Basis of Presentation of Unaudited Condensed Financial Information   The unaudited condensed financial statements of the Company for the three months ended June 30, 2018 and 2017 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2018 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2018 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 28, 2018. These financial statements should be read in conjunction with that report.

2018 24350147

EX-101.SCH 5 vbio-20180630.xsd XBRL SCHEMA FILE 00000001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business Operations and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Derivative Liability link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Stockholders' Equity (Deficiency) link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Obligations link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Derivative Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stockholders' Equity (Deficiency) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Business Operations and Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Derivative Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Derivative Liability - Schedule of Valuation Assumptions for Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stockholders' Equity (Deficiency) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stockholders' Equity (Deficiency) - Schedule of Nonvested Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stock Options - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Warrants - Summary of Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Related Party Obligations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 vbio-20180630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 vbio-20180630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 vbio-20180630_lab.xml XBRL LABEL FILE Antidilutive Securities [Axis] Warrants [Member] Award Type [Axis] Stock Options One [Member] Stock Options Two [Member] Stock Options Three [Member] Stock Options Four [Member] Stock Options Five [Member] Stock Options Six [Member] Range [Axis] Maximum [Member] Minimum [Member] Stock Options Seven [Member] Options [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Class of Stock [Axis] Restricted Stock [Member] Lease Arrangement, Type [Axis] Carlson Lease [Member] Measurement Input Type [Axis] Risk Free Interest Rate [Member] Expected Volatility Rate [Member] Expected Life [Member] Expected Dividend Yield [Member] Title of Individual [Axis] One Consultants [Member] Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets Cash Accounts receivable, net Prepaid expense, related party Prepaid expenses Total Assets Liabilities and Stockholders' Equity (Deficiency) Current Liabilities Accounts payable and accrued liabilities Derivative liability Total liabilities Stockholders' Equity (Deficiency) Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 24,312,647 and 24,275,147 shares issued and outstanding, respectively Additional paid-in-capital Accumulated deficit Total stockholders' equity (deficiency) Total liabilities and stockholders' equity (deficiency) Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of goods sold Gross profit Operating expenses: General and administrative Research and development Rent - related party Total operating expenses Loss from operations Other income (expenses) Change in fair value of derivative liability Interest expense Total other expenses, net Net loss Net loss per common share - Basic and diluted Weighted average number of common shares outstanding - Basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Fair value of vested restricted common stock Fair value of vested stock options Fair value of common stock issued for services Fair value of common stock issued for services, shares Net Loss Balance Balance, shares Statement of Cash Flows [Abstract] Operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Fair value of vested stock options Amortization of common stock issued to employees with vesting terms Fair value of common stock issued for services Change in fair value of derivative liability Fair value of vested warrants granted to employees Changes in operating assets and liabilities: Accounts receivable Deposit Accounts payable and accrued liabilities Prepaid expense, related party Accounts payable - related party Net cash used in operating activities Net decrease in cash Cash and cash equivalents - beginning of period Cash and cash equivalent - end of period Supplemental disclosure of cash flow information: Cash paid during the period for: Interest Income taxes Accounting Policies [Abstract] Business Operations and Summary of Significant Accounting Policies Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Liability Equity [Abstract] Stockholders' Equity (deficiency) Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock Options Warrants and Rights Note Disclosure [Abstract] Warrants Related Party Transactions [Abstract] Related Party Obligations Commitments and Contingencies Disclosure [Abstract] Commitments Subsequent Events [Abstract] Subsequent Events Going Concern Basis of Presentation of Unaudited Condensed Financial Information Use of Estimates Financial Assets and Liabilities Measured at Fair Value Derivative Financial Instruments Stock-Based Compensation Basic and Diluted Loss Per Share Research and Development Recent Accounting Pronouncements Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Valuation Assumptions for Derivative Liabilities Schedule of Nonvested Restricted Stock Unit Activity Summary of Stock Option Activity Schedule of Stock Options Outstanding and Exercisable Summary of Warrants Activity Stock split description Net loss Net cash used in operating activities Fair value of derivative liabilities Antidilutive securities excluded from computation of earnings per share Derivative liabilities Increase (decrease) in derivative liabilities Fair Value, by Balance Sheet Grouping [Table] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair value measurements valuation techniques, percent Fair value measurements valuation techniques, term Fair Value of Derivative Liability Fair value of stock awards that vested Stock-based compensation expense not yet recognized Stock-based compensation unvested compensation related to awards period Common stock issued for services, shares Common stock issued for services Non-vested shares, Beginning Balance Granted Vested Forfeited Non-vested shares, Ending Balance Stock-based compensation Unamortized cost of outstanding stock-based awards Weighted average remaining vesting period Number of stock options outstanding, shares Options outstanding, intrinsic value Shares outstanding, beginning balance outstanding Shares, Granted Shares, Exercised Shares, Expired Shares, Cancelled Shares outstanding, ending balance Shares, Balance exercisable Weighted Average Exercise Price, outstanding beginning balance Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Expired Weighted Average Exercise Price, Cancelled Weighted Average Exercise Price, outstanding ending balance Weighted Average Exercise Price, Balance exercisable Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of options outstanding Weighted average exercise price, options outstanding Weighted average grant-date stock price, options outstanding Number of options exercisable Weighted average exercise price, options exercisable Weighted average grant-date stock price, options exercisable Shares, Outstanding Beginning Balance Shares, Granted Shares, Exercised Shares, Expired Shares, Outstanding and Exercisable Balance Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Granted EX-101.PRE 9 vbio-20180630_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Aug. 13, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	Vitality Biopharma, Inc.
Entity Central Index Key	0001438943
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		24,350,147
Trading Symbol	VBIO
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2018

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Current Assets
Cash	$ 173,037	$ 656,290
Accounts receivable, net	6,611	13,843
Prepaid expense, related party		2,600
Prepaid expenses	3,058	3,058
Total Assets	182,706	675,791
Current Liabilities
Accounts payable and accrued liabilities	347,790	200,475
Derivative liability	170,435	153,042
Total liabilities	518,225	353,517
Stockholders' Equity (Deficiency)
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 24,312,647 and 24,275,147 shares issued and outstanding, respectively	24,112	24,075
Additional paid-in-capital	22,820,524	22,343,135
Accumulated deficit	(23,180,155)	(22,044,936)
Total stockholders' equity (deficiency)	(335,519)	322,274
Total liabilities and stockholders' equity (deficiency)	$ 182,706	$ 675,791

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Mar. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	24,312,647	24,275,147
Common stock, shares outstanding	24,312,647	24,275,147

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenue	$ 26,328	$ 27,043
Cost of goods sold	25,748	20,486
Gross profit	580	6,557
Operating expenses:
General and administrative	523,184	673,789
Research and development	587,422	407,009
Rent - related party	7,800	7,500
Total operating expenses	1,118,406	1,088,298
Loss from operations	(1,117,826)	(1,081,741)
Other income (expenses)
Change in fair value of derivative liability	(17,393)	(24,612)
Interest expense
Total other expenses, net	(17,393)	(24,612)
Net loss	$ (1,135,219)	$ (1,106,353)
Net loss per common share - Basic and diluted	$ (0.05)	$ (0.05)
Weighted average number of common shares outstanding - Basic and diluted	24,290,806	22,255,290

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) - 3 months ended Jun. 30, 2018 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Mar. 31, 2018	$ 24,075	$ 22,343,135	$ (22,044,936)	$ 322,274
Balance, shares at Mar. 31, 2018	24,275,147
Fair value of vested restricted common stock		106,881		106,881
Fair value of vested stock options		321,420		321,420
Fair value of common stock issued for services	$ 37	49,088		$ 49,125
Fair value of common stock issued for services, shares	37,500			37,500
Net Loss			(1,135,219)	$ (1,135,219)
Balance at Jun. 30, 2018	$ 24,112	$ 22,820,524	$ (23,180,155)	$ (335,519)
Balance, shares at Jun. 30, 2018	24,312,647

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
Condensed Statement of Cash Flows (Unaudited) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Operating activities
Net loss	$ (1,135,219)	$ (1,106,353)
Adjustments to reconcile net loss to net cash used in operating activities:
Fair value of vested stock options	321,420	342,540
Amortization of common stock issued to employees with vesting terms	106,881	102,584
Fair value of common stock issued for services	49,125	100,000
Change in fair value of derivative liability	17,393	24,612
Fair value of vested warrants granted to employees
Changes in operating assets and liabilities:
Accounts receivable	7,232	(6,134)
Deposit
Accounts payable and accrued liabilities	147,315	(66,913)
Prepaid expense, related party	2,600
Accounts payable - related party		(12,500)
Net cash used in operating activities	(483,253)	(622,164)
Net decrease in cash	(483,253)	(622,164)
Cash and cash equivalents - beginning of period	656,290	1,152,766
Cash and cash equivalent - end of period	173,037	530,602
Cash paid during the period for:
Interest
Income taxes

XML 16 R7.htm IDEA: XBRL DOCUMENT

Business Operations and Summary of Significant Accounting Policies

3 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Business Operations and Summary of Significant Accounting Policies

1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. The Company’s fiscal year end is March 31.

Going Concern

The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that as of June 30, 2018 we have sufficient funds to operate the business for the next [6] months. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, licensing or acquiring new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.

Basis of Presentation of Unaudited Condensed Financial Information

Use of Estimates

Financial Assets and Liabilities Measured at Fair Value

Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3		Unobservable inputs based on the Company’s assumptions.

The fair value of the derivative liabilities of $170,435 and $153,042 at June 30, 2018 and March 31, 2018, respectively, were valued using Level 2 inputs.

Derivative Financial Instruments

Stock-Based Compensation

Basic and Diluted Loss Per Share

	Three months ended
	June 30, 2018		June 30, 2017
Options		3,316,710		2,820,489
Warrants		1,135,003		372,421
Total		4,451,713		3,192,910

Research and Development

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.

XML 17 R8.htm IDEA: XBRL DOCUMENT

Derivative Liability

3 Months Ended

Jun. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Liability

2. DERIVATIVE LIABILITY

At June 30, 2018 and March 31, 2018, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions:

	June 30, 2018			March 31, 2018
Conversion feature:
Risk-free interest rate		2.52	%		1.73-2.27	%
Expected volatility		119	%		121	%
Expected life (in years)		2 years			.25 to 2.15 years
Expected dividend yield		—			—

Fair Value:
Conversion feature	$	170,435		$	153,042

XML 18 R9.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Deficiency)

3 Months Ended

Jun. 30, 2018

Equity [Abstract]

Stockholders' Equity (deficiency)

3. STOCKHOLDERS’ EQUITY (DEFICIENCY)

Common stock issued to employees with vesting terms

The following table summarizes restricted common stock activity:

	Number of Shares
Non-vested shares, April 1, 2018		918,085
Granted		—
Vested		—
Forfeited		—
Non-vested shares, June 30, 2018		918,085

Common stock issued for services

XML 19 R10.htm IDEA: XBRL DOCUMENT

Stock Options

3 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Options

4. STOCK OPTIONS

A summary of the Company’s stock option activity during the three months ended June 30, 2018 is as follows:

	Shares		Weighted Average Exercise Price
Balance outstanding at March 31, 2018		3,316,710	$	1.40
Granted		—
Exercised		—
Expired		—
Cancelled		—
Balance outstanding at June 30, 2018		3,316,710	$	1.40
Balance exercisable at June 30, 2018		2,255,648	$	1.22

A summary of the Company’s stock options outstanding and exercisable as of June 30, 2017 is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- date Stock Price
Options Outstanding, June 30, 2018		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		477,500	$	1.50-1.81	$	1.50
		747,500	$	2.00 – 2.79	$	2.00 – 2.79
		123,334	$	3.10 – 3.80	$	3.10 – 3.80
		45,834	$	4.00 – 4.70	$	4.00 – 4.70
		3,316,710
Options Exercisable, June 30, 2018		1,259,980	$	0.50	$	0.50
		101,500	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		147,500	$	1.50-1.81	$	1.50-1.81
		447,500	$	2.00 – 2.79	$	2.00 – 2.79
		123,334	$	3.10 – 3.80	$	3.10 – 3.80
		45,834	$	4.00 – 4.70	$	4.00 – 4.70
		2,255,648

During the three months ended June 30, 2018, we expensed total stock-based compensation related to stock options of $321,420, and the remaining unamortized cost of the outstanding stock-based awards at June 30, 2018 was approximately $799,000. This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years. At June 30, 2018, the 3,316,710 outstanding stock options had an intrinsic value of approximately $2,100,000.

XML 20 R11.htm IDEA: XBRL DOCUMENT

Warrants

3 Months Ended

Jun. 30, 2018

Warrants and Rights Note Disclosure [Abstract]

Warrants

5. WARRANTS

At June 30, 2018, warrants to purchase common shares were outstanding as follows:

	Shares			Weighted Average Exercise Price
Balance at March 31, 2018		1,164,422		$	2.19
Granted		—			—
Exercised		—			—
Expired		(29,419	)	$	4.25
Balance outstanding and exercisable at June 30, 2018		1,135,003		$	2.19

XML 21 R12.htm IDEA: XBRL DOCUMENT

Related Party Obligations

3 Months Ended

Jun. 30, 2018

Related Party Obligations

6. RELATED PARTY OBLIGATIONS

XML 22 R13.htm IDEA: XBRL DOCUMENT

Commitments

3 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments

7. COMMITMENTS

On August 19, 2016, we filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. We received subpoenas to produce documents dated December 14, 2016, and January 23, 2017, and a further subpoena for testimony and any supplemental production of documents dated June 5, 2017. The document requests were primarily in connection with this matter. We have complied with all document requests and the Company’s CEO will provide testimony when the SEC schedules such testimony, which we believe will be sometime before the end of September 2018.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Jun. 30, 2018

Subsequent Events [Abstract]

Subsequent Events

8. SUBSEQUENT EVENTS

In February 2018, the Company issued a total of 37,500 shares of common stock to one consultant as payment for services and recorded expenses of $64,125 based on the fair value of the Company’s common stock at the issuance date.

XML 24 R15.htm IDEA: XBRL DOCUMENT

Business Operations and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Going Concern

Going Concern

The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that as of June 30, 2018 we have sufficient funds to operate the business for the next [6] months. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, licensing or acquiring new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.

Basis of Presentation of Unaudited Condensed Financial Information

Basis of Presentation of Unaudited Condensed Financial Information

Use of Estimates

Financial Assets and Liabilities Measured at Fair Value

Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3		Unobservable inputs based on the Company’s assumptions.

The fair value of the derivative liabilities of $170,435 and $153,042 at June 30, 2018 and March 31, 2018, respectively, were valued using Level 2 inputs.

Derivative Financial Instruments

Stock-Based Compensation

Basic and Diluted Loss Per Share

	Three months ended
	June 30, 2018		June 30, 2017
Options		3,316,710		2,820,489
Warrants		1,135,003		372,421
Total		4,451,713		3,192,910

Research and Development

Recent Accounting Pronouncements

XML 25 R16.htm IDEA: XBRL DOCUMENT

Business Operations and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Antidilutive Securities Excluded from Computation of Earnings Per Share

The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:

	Three months ended
	June 30, 2018		June 30, 2017
Options		3,316,710		2,820,489
Warrants		1,135,003		372,421
Total		4,451,713		3,192,910

XML 26 R17.htm IDEA: XBRL DOCUMENT

Derivative Liability (Tables)

3 Months Ended

Jun. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Valuation Assumptions for Derivative Liabilities

At June 30, 2018 and March 31, 2018, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions:

	June 30, 2018			March 31, 2018
Conversion feature:
Risk-free interest rate		2.52	%		1.73-2.27	%
Expected volatility		119	%		121	%
Expected life (in years)		2 years			.25 to 2.15 years
Expected dividend yield		—			—

Fair Value:
Conversion feature	$	170,435		$	153,042

XML 27 R18.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Deficiency) (Tables)

3 Months Ended

Jun. 30, 2018

Equity [Abstract]

Schedule of Nonvested Restricted Stock Unit Activity

The following table summarizes restricted common stock activity:

	Number of Shares
Non-vested shares, April 1, 2018		918,085
Granted		—
Vested		—
Forfeited		—
Non-vested shares, June 30, 2018		918,085

XML 28 R19.htm IDEA: XBRL DOCUMENT

Stock Options (Tables)

3 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Stock Option Activity

A summary of the Company’s stock option activity during the three months ended June 30, 2018 is as follows:

	Shares		Weighted Average Exercise Price
Balance outstanding at March 31, 2018		3,316,710	$	1.40
Granted		—
Exercised		—
Expired		—
Cancelled		—
Balance outstanding at June 30, 2018		3,316,710	$	1.40
Balance exercisable at June 30, 2018		2,255,648	$	1.22

Schedule of Stock Options Outstanding and Exercisable

A summary of the Company’s stock options outstanding and exercisable as of June 30, 2017 is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- date Stock Price
Options Outstanding, June 30, 2018		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		477,500	$	1.50-1.81	$	1.50
		747,500	$	2.00 – 2.79	$	2.00 – 2.79
		123,334	$	3.10 – 3.80	$	3.10 – 3.80
		45,834	$	4.00 – 4.70	$	4.00 – 4.70
		3,316,710
Options Exercisable, June 30, 2018		1,259,980	$	0.50	$	0.50
		101,500	$	0.96	$	0.96
		130,000	$	1.00	$	10.00
		147,500	$	1.50-1.81	$	1.50-1.81
		447,500	$	2.00 – 2.79	$	2.00 – 2.79
		123,334	$	3.10 – 3.80	$	3.10 – 3.80
		45,834	$	4.00 – 4.70	$	4.00 – 4.70
		2,255,648

XML 29 R20.htm IDEA: XBRL DOCUMENT

Warrants (Tables)

3 Months Ended

Jun. 30, 2018

Warrants and Rights Note Disclosure [Abstract]

Summary of Warrants Activity

At June 30, 2018, warrants to purchase common shares were outstanding as follows:

	Shares			Weighted Average Exercise Price
Balance at March 31, 2018		1,164,422		$	2.19
Granted		—			—
Exercised		—			—
Expired		(29,419	)	$	4.25
Balance outstanding and exercisable at June 30, 2018		1,135,003		$	2.19

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 30 R21.htm IDEA: XBRL DOCUMENT

Business Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	May 31, 2016
Accounting Policies [Abstract]
Stock split description	In May 2016, we received shareholder and board approval for a name change to Vitality Biopharma, Inc., an exchange of one (1) share of the Company's common stock for each 10 shares of common stock outstanding or exercisable under any outstanding warrants or option agreements, and an increase in the number of shares of authorized common stock from 525,000,000 to 1,000,000,000. These corporate changes became effective on July 20, 2016.
Common stock, shares authorized	1,000,000,000		1,000,000,000	525,000,000
Net loss	$ 1,135,219	$ 1,106,353
Net cash used in operating activities	483,253	$ 622,164
Fair value of derivative liabilities	$ 170,435		$ 153,042

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 31 R22.htm IDEA: XBRL DOCUMENT

Business Operations and Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Antidilutive securities excluded from computation of earnings per share	4,451,713	3,192,910
Options [Member]
Antidilutive securities excluded from computation of earnings per share	3,316,710	2,820,489
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	1,135,003	372,421

XML 32 R23.htm IDEA: XBRL DOCUMENT

Derivative Liability (Details Narrative) - USD ($)	12 Months Ended
Derivative Liability (Details Narrative) - USD ($)	Mar. 31, 2018	Jun. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities	$ 153,042	$ 170,435
Increase (decrease) in derivative liabilities	$ 17,393

XML 33 R24.htm IDEA: XBRL DOCUMENT

Derivative Liability - Schedule of Valuation Assumptions for Derivative Liabilities (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value of Derivative Liability	$ 170,435	$ 153,042
Risk Free Interest Rate [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value measurements valuation techniques, percent	2.52%
Expected Volatility Rate [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value measurements valuation techniques, percent	119.00%	121.00%
Expected Life [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value measurements valuation techniques, term	2 years
Expected Dividend Yield [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value measurements valuation techniques, percent	0.00%	0.00%
Minimum [Member] \| Risk Free Interest Rate [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value measurements valuation techniques, percent		1.73%
Minimum [Member] \| Expected Life [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value measurements valuation techniques, term		2 months 30 days
Maximum [Member] \| Risk Free Interest Rate [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value measurements valuation techniques, percent		2.27%
Maximum [Member] \| Expected Life [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value measurements valuation techniques, term		2 years 1 month 24 days

XML 34 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Deficiency) (Details Narrative)	3 Months Ended
Stockholders' Equity (Deficiency) (Details Narrative)	Jun. 30, 2018 USD ($) shares
Equity [Abstract]
Fair value of stock awards that vested	$ 106,881
Stock-based compensation expense not yet recognized	$ 240,000
Stock-based compensation unvested compensation related to awards period	1 year
Common stock issued for services, shares \| shares	37,500
Common stock issued for services	$ 49,125

XML 35 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Deficiency) - Schedule of Nonvested Restricted Stock Unit Activity (Details) - Restricted Stock [Member]	3 Months Ended
	Jun. 30, 2018 shares
Non-vested shares, Beginning Balance	918,085
Granted
Vested
Forfeited
Non-vested shares, Ending Balance	918,085

XML 36 R27.htm IDEA: XBRL DOCUMENT

Stock Options (Details Narrative) - USD ($)	3 Months Ended
Stock Options (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation	$ 321,420	$ 342,540
Unamortized cost of outstanding stock-based awards	$ 799,000
Weighted average remaining vesting period	2 years
Number of stock options outstanding, shares	3,316,710		3,316,710
Options outstanding, intrinsic value	$ 2,100,000

XML 37 R28.htm IDEA: XBRL DOCUMENT

Stock Options - Summary of Stock Option Activity (Details)	3 Months Ended
	Jun. 30, 2018 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares outstanding, beginning balance outstanding \| shares	3,316,710
Shares, Granted \| shares
Shares, Exercised \| shares
Shares, Expired \| shares
Shares, Cancelled \| shares
Shares outstanding, ending balance \| shares	3,316,710
Shares, Balance exercisable \| shares	2,255,648
Weighted Average Exercise Price, outstanding beginning balance \| $ / shares	$ 1.40
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Cancelled \| $ / shares
Weighted Average Exercise Price, outstanding ending balance \| $ / shares	1.40
Weighted Average Exercise Price, Balance exercisable \| $ / shares	$ 1.22

XML 38 R29.htm IDEA: XBRL DOCUMENT

Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) - $ / shares	3 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	3,316,710	3,316,710
Weighted average grant-date stock price, options outstanding
Number of options exercisable	2,255,648
Stock Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	1,664,542
Weighted average exercise price, options outstanding	$ 0.50
Weighted average grant-date stock price, options outstanding	$ 0.50
Number of options exercisable	1,259,980
Weighted average exercise price, options exercisable	$ 0.50
Weighted average grant-date stock price, options exercisable	$ 0.50
Stock Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	128,000
Weighted average exercise price, options outstanding	$ 0.96
Weighted average grant-date stock price, options outstanding	$ 0.96
Number of options exercisable	101,500
Weighted average exercise price, options exercisable	$ 0.96
Weighted average grant-date stock price, options exercisable	$ 0.96
Stock Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	130,000
Weighted average exercise price, options outstanding	$ 1.00
Weighted average grant-date stock price, options outstanding	$ 10.00
Number of options exercisable	130,000
Weighted average exercise price, options exercisable	$ 1.00
Weighted average grant-date stock price, options exercisable	$ 10.00
Stock Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	477,500
Weighted average grant-date stock price, options outstanding	$ 1.50
Number of options exercisable	147,500
Stock Options Four [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	$ 1.50
Weighted average exercise price, options exercisable	1.50
Weighted average grant-date stock price, options exercisable	1.50
Stock Options Four [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	1.81
Weighted average exercise price, options exercisable	1.81
Weighted average grant-date stock price, options exercisable	$ 1.81
Stock Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	747,500
Number of options exercisable	447,500
Stock Options Five [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	$ 2.00
Weighted average grant-date stock price, options outstanding	2.00
Weighted average exercise price, options exercisable	2.00
Weighted average grant-date stock price, options exercisable	2.00
Stock Options Five [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	2.79
Weighted average grant-date stock price, options outstanding	2.79
Weighted average exercise price, options exercisable	2.79
Weighted average grant-date stock price, options exercisable	$ 2.79
Stock Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	123,334
Number of options exercisable	123,334
Stock Options Six [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	$ 3.10
Weighted average grant-date stock price, options outstanding	3.10
Weighted average exercise price, options exercisable	3.10
Weighted average grant-date stock price, options exercisable	3.10
Stock Options Six [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	3.80
Weighted average grant-date stock price, options outstanding	3.80
Weighted average exercise price, options exercisable	3.80
Weighted average grant-date stock price, options exercisable	$ 3.80
Stock Options Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	45,834
Number of options exercisable	45,834
Stock Options Seven [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	$ 4.00
Weighted average grant-date stock price, options outstanding	4.00
Weighted average exercise price, options exercisable	4.00
Weighted average grant-date stock price, options exercisable	4.00
Stock Options Seven [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	4.70
Weighted average grant-date stock price, options outstanding	4.70
Weighted average exercise price, options exercisable	4.70
Weighted average grant-date stock price, options exercisable	$ 4.70

XML 39 R30.htm IDEA: XBRL DOCUMENT

Warrants - Summary of Warrants Activity (Details)	3 Months Ended
Warrants - Summary of Warrants Activity (Details)	Jun. 30, 2018 $ / shares shares
Warrants and Rights Note Disclosure [Abstract]
Shares, Outstanding Beginning Balance \| shares	1,164,422
Shares, Granted \| shares
Shares, Exercised \| shares
Shares, Expired \| shares	(29,419)
Shares, Outstanding and Exercisable Balance \| shares	1,135,003
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 2.19
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares	4.25
Weighted Average Exercise Price, Outstanding and Exercisable Balance \| $ / shares	$ 2.19

XML 40 R31.htm IDEA: XBRL DOCUMENT

Related Party Obligations (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
Related Party Obligations (Details Narrative) - USD ($)	Apr. 23, 2012	Jun. 30, 2018	Jun. 30, 2017
Operating Leased Assets [Line Items]
Operating leases, net rent expense		$ 7,800	$ 7,800
Carlson Lease [Member]
Operating Leased Assets [Line Items]
Lease description	The Carlson Lease began on May 1, 2012 and was extended from May 1, 2017 to May 1, 2020.
Payments for rent per month	$ 2,300
Lease expiration date	May 01, 2017
Increase payment for rent per month	$ 2,600

XML 41 R32.htm IDEA: XBRL DOCUMENT

Commitments (Details Narrative)	Aug. 19, 2016 shares
Commitments and Contingencies Disclosure [Abstract]
Number of shares of common stock	2,650,000
Common stock issuable upon exercise of warrants	7,950,000

XML 42 R33.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Feb. 28, 2018	Jun. 30, 2018
Number of shares issued during period for services		37,500
Number of shares issued during period for services, value		$ 49,125
One Consultants [Member]
Number of shares issued during period for services	37,500
Number of shares issued during period for services, value	$ 64,125

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 64 129 1 false 21 0 false 4 false false R1.htm 00000001 - Document - Document And Entity Information Sheet http://vitality.bio/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://vitality.bio/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://vitality.bio/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://vitality.bio/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) Sheet http://vitality.bio/role/StatementOfChangesInStockholdersEquityDeficiency Condensed Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statement of Cash Flows (Unaudited) Sheet http://vitality.bio/role/StatementOfCashFlows Condensed Statement of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Business Operations and Summary of Significant Accounting Policies Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies Business Operations and Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Derivative Liability Sheet http://vitality.bio/role/DerivativeLiability Derivative Liability Notes 8 false false R9.htm 00000009 - Disclosure - Stockholders' Equity (Deficiency) Sheet http://vitality.bio/role/StockholdersEquityDeficiency Stockholders' Equity (Deficiency) Notes 9 false false R10.htm 00000010 - Disclosure - Stock Options Sheet http://vitality.bio/role/StockOptions Stock Options Notes 10 false false R11.htm 00000011 - Disclosure - Warrants Sheet http://vitality.bio/role/Warrants Warrants Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Obligations Sheet http://vitality.bio/role/RelatedPartyObligations Related Party Obligations Notes 12 false false R13.htm 00000013 - Disclosure - Commitments Sheet http://vitality.bio/role/Commitments Commitments Notes 13 false false R14.htm 00000014 - Disclosure - Subsequent Events Sheet http://vitality.bio/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 00000015 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Policies) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesPolicies Business Operations and Summary of Significant Accounting Policies (Policies) Policies http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Tables) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesTables Business Operations and Summary of Significant Accounting Policies (Tables) Tables http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Derivative Liability (Tables) Sheet http://vitality.bio/role/DerivativeLiabilityTables Derivative Liability (Tables) Tables http://vitality.bio/role/DerivativeLiability 17 false false R18.htm 00000018 - Disclosure - Stockholders' Equity (Deficiency) (Tables) Sheet http://vitality.bio/role/StockholdersEquityDeficiencyTables Stockholders' Equity (Deficiency) (Tables) Tables http://vitality.bio/role/StockholdersEquityDeficiency 18 false false R19.htm 00000019 - Disclosure - Stock Options (Tables) Sheet http://vitality.bio/role/StockOptionsTables Stock Options (Tables) Tables http://vitality.bio/role/StockOptions 19 false false R20.htm 00000020 - Disclosure - Warrants (Tables) Sheet http://vitality.bio/role/WarrantsTables Warrants (Tables) Tables http://vitality.bio/role/Warrants 20 false false R21.htm 00000021 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Details Narrative) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Business Operations and Summary of Significant Accounting Policies (Details Narrative) Details http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Business Operations and Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Business Operations and Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 22 false false R23.htm 00000023 - Disclosure - Derivative Liability (Details Narrative) Sheet http://vitality.bio/role/DerivativeLiabilityDetailsNarrative Derivative Liability (Details Narrative) Details http://vitality.bio/role/DerivativeLiabilityTables 23 false false R24.htm 00000024 - Disclosure - Derivative Liability - Schedule of Valuation Assumptions for Derivative Liabilities (Details) Sheet http://vitality.bio/role/DerivativeLiability-ScheduleOfValuationAssumptionsForDerivativeLiabilitiesDetails Derivative Liability - Schedule of Valuation Assumptions for Derivative Liabilities (Details) Details 24 false false R25.htm 00000025 - Disclosure - Stockholders' Equity (Deficiency) (Details Narrative) Sheet http://vitality.bio/role/StockholdersEquityDeficiencyDetailsNarrative Stockholders' Equity (Deficiency) (Details Narrative) Details http://vitality.bio/role/StockholdersEquityDeficiencyTables 25 false false R26.htm 00000026 - Disclosure - Stockholders' Equity (Deficiency) - Schedule of Nonvested Restricted Stock Unit Activity (Details) Sheet http://vitality.bio/role/StockholdersEquityDeficiency-ScheduleOfNonvestedRestrictedStockUnitActivityDetails Stockholders' Equity (Deficiency) - Schedule of Nonvested Restricted Stock Unit Activity (Details) Details http://vitality.bio/role/StockholdersEquityDeficiencyTables 26 false false R27.htm 00000027 - Disclosure - Stock Options (Details Narrative) Sheet http://vitality.bio/role/StockOptionsDetailsNarrative Stock Options (Details Narrative) Details http://vitality.bio/role/StockOptionsTables 27 false false R28.htm 00000028 - Disclosure - Stock Options - Summary of Stock Option Activity (Details) Sheet http://vitality.bio/role/StockOptions-SummaryOfStockOptionActivityDetails Stock Options - Summary of Stock Option Activity (Details) Details 28 false false R29.htm 00000029 - Disclosure - Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) Sheet http://vitality.bio/role/StockOptions-ScheduleOfStockOptionsOutstandingAndExercisableDetails Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) Details 29 false false R30.htm 00000030 - Disclosure - Warrants - Summary of Warrants Activity (Details) Sheet http://vitality.bio/role/Warrants-SummaryOfWarrantsActivityDetails Warrants - Summary of Warrants Activity (Details) Details 30 false false R31.htm 00000031 - Disclosure - Related Party Obligations (Details Narrative) Sheet http://vitality.bio/role/RelatedPartyObligationsDetailsNarrative Related Party Obligations (Details Narrative) Details http://vitality.bio/role/RelatedPartyObligations 31 false false R32.htm 00000032 - Disclosure - Commitments (Details Narrative) Sheet http://vitality.bio/role/CommitmentsDetailsNarrative Commitments (Details Narrative) Details http://vitality.bio/role/Commitments 32 false false R33.htm 00000033 - Disclosure - Subsequent Events (Details Narrative) Sheet http://vitality.bio/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://vitality.bio/role/SubsequentEvents 33 false false All Reports Book All Reports vbio-20180630.xml vbio-20180630.xsd vbio-20180630_cal.xml vbio-20180630_def.xml vbio-20180630_lab.xml vbio-20180630_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 49 0001493152-18-011777-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-011777-xbrl.zip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�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end

Stock Options - Summary of Stock Option Activity (Details)	3 Months Ended
	Jun. 30, 2018 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares outstanding, beginning balance outstanding \| shares	3,316,710
Shares, Granted \| shares
Shares, Exercised \| shares
Shares, Expired \| shares
Shares, Cancelled \| shares
Shares outstanding, ending balance \| shares	3,316,710
Shares, Balance exercisable \| shares	2,255,648
Weighted Average Exercise Price, outstanding beginning balance \| $ / shares	$ 1.40
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Cancelled \| $ / shares
Weighted Average Exercise Price, outstanding ending balance \| $ / shares	1.40
Weighted Average Exercise Price, Balance exercisable \| $ / shares	$ 1.22